Kendal Square, MA– Eli Lilly plans to open a drug delivery and innovation center in Kendall Square, Massachusetts. The focus of this new innovation center will be on drug delivery device innovation (specific to diabetes), immunology, chronic pain, and neural degeneration.
“As we start to look at this, we’re looking at what kind of technology changes and evolution is going to allow for a simple, convenient delivery and part of that is the technology part and the technology that’s coming together about mobile technology and so on,” he said. “We’ll seek to work with similar leading experts there in Boston in the Cambridge area to think about, research, and explore some of those technologies and potential applications for our company.” -Senior Director of Global Corporate Communications Edward Sagebiel
Eli Lilly currently has 4 apps in Apple’s app store, one of which, Glucagon is a tool for teaching patients how to use injectable medications. The Glucagon app serves as a virtual practice tool with steps for administering Glucagon, managing the expiration of multiple kits, and receiving helpful tips.
“New drug delivery and device innovation is critically important to Lilly’s growing portfolio of potential medicines, particularly in our focus areas of diabetes, neurodegeneration, immunology and pain,”Jan Lundberg, Ph.D., executive vice president of science and technology and president of Lilly Research Laboratories said in a statement. “The best therapies of the future will marry breakthrough scientific discovery with customer-friendly devices. That’s what will make life better for people who need our medicines and give Lilly a true competitive edge.”
This initiative serves as a perfect example of the power and influence that the “innovation from insiders” trend we have been watching closely this year has had on the pharmaceutical industry.